OpenAI acquires Orchestra Bio to connect research AI with drug-development operations
Founder Ashoka Rajendra drew on biology research and life-sciences software work to build the platform; Orchestra had reportedly raised $20 million before the deal.
By Ryan Merket · Published
Primary source: X
Why it matters
OpenAI is extending Rosalind from scientific research tools into drug-program operations, betting that agents coordinating studies, vendors and timelines can make its life-sciences offering useful beyond the lab.
OpenAI has acquired Orchestra Bio, bringing founder Ashoka Rajendra (@ashokaraj_) and his drug-development operations platform into Rosalind, OpenAI's life-sciences AI business. The acquisition, announced on October 20th in OpenAI's post on X, puts workflow software alongside the models and research tools OpenAI has been building for scientists.…
When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.